Whalesbook
📉 The Financial Deep Dive
Krishna Institute of Medical Sciences Limited (KIMS) unveiled its investor presentation for Q3 FY26, revealing a bifurcated performance. While the top line showed impressive momentum, the bottom line faced significant pressure.
The Numbers:
- Operating Revenue: A robust â‚ą9,977 million was reported for Q3 FY26, marking a substantial 29.2% increase year-on-year (YoY). For the nine-month period ended December 31, 2025, revenue climbed 26.4% YoY to â‚ą28,300 million.
- EBITDA: Despite revenue growth, EBITDA saw a marginal decline of 0.4% YoY to â‚ą2,041 million in Q3 FY26.
- EBITDA Margin: This translated into a significant contraction in EBITDA margin, falling to 20.4% in Q3 FY26 from 25.9% in the prior year's comparable quarter.
- Profit After Tax (PAT): The most concerning figure was the 43.9% YoY fall in PAT to â‚ą519 million for Q3 FY26.
The Quality:
The substantial drop in PAT and margin compression were attributed by the company to several factors: higher finance costs, increased depreciation, and a fair value loss on a call option recorded in Q2 FY26 (which affects prior period comparisons). While the operational performance remained strong, with a 13.2% YoY increase in In-patient (IP) volume and a 24.5% YoY rise in Out-patient (OP) volume, and Average Revenue Per Occupied Bed (ARPOB) growing by 20.5% YoY to â‚ą46,341, these positives were unable to offset the rising costs and financial charges at the net profit level.
The Grill:
The investor presentation excerpt did not include specific future financial guidance or detailed commentary from a concall. Management's strategic levers for future growth were mentioned, including capacity additions and strategic acquisitions, but without quantitative targets or forward-looking statements.
đźš© Risks & Outlook
Specific Risks:
The primary risks highlighted by the Q3 performance are the increasing finance costs and depreciation, which directly impact profitability. The margin compression suggests potential pricing pressures or escalating operational expenditures that are not being fully absorbed by revenue growth. The one-off fair value loss, while impacting comparability, still points to potential financial engineering or investment-related impacts that need scrutiny. The operational growth, though strong, is not translating effectively to the bottom line, indicating a need for careful cost management and efficiency improvements.
The Forward View:
Investors will be closely watching how KIMS manages its cost structure, particularly finance costs and depreciation, in upcoming quarters. The successful ramp-up of its new units across Maharashtra, Kerala, Andhra Pradesh, and Karnataka will be crucial. The company's stated strategic levers—consistent performance, capacity additions, strategic acquisitions, and doctor partnerships—need to be backed by concrete execution and a clear path to profitability, especially in light of the recent margin contraction. The absence of forward guidance means investors will rely heavily on operational execution and management commentary in future concalls to gauge the outlook.